Clinical Trials
8 trialsNCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT03904251 2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT03393611 2022-12-21
CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Weill Medical College of Cornell University
Phase 1 Completed
NCT03988205 2022-07-19
Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia
Medical College of Wisconsin
Phase 4 Terminated
NCT01943682 2020-11-09
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Completed
NCT00875693 2018-01-17
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Weill Medical College of Cornell University
Phase 1 Completed
NCT00788892 2018-01-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT00822094 2017-11-24
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Jazz Pharmaceuticals
Phase 2 Completed